NDA 220381 · Fresenius Kabi USA
Glycophos
Sodium Glycerophosphate · Intravenous
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 29, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
27
6 Phase 3, 2 recruiting
FAERS reports
364
358 serious, 52 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
Glycophos is indicated as a source of phosphorus in adults and pediatric patients 12 years and older as part of parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. Glycophos is a phosphorus replacement product indicated as a source of phosphorus in adults and pediatric patients 12 years and older as part of parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )
Mechanism: Sodium glycerophosphate, an organic phosphate salt, functions as a source of phosphorus. Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- GLYCOPHOS · SODIUM GLYCEROPHOSPHATE 4.32GM/20ML (216MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- GLYCOPHOS · SODIUM GLYCEROPHOSPHATE 21.6GM/100ML (216MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glycerophosphate" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's DiseasePivotal-lookingStatus unknown
Daewoong Bio Inc.Industry
NCT05383183 · 630 participants (planned) · Start Jan 20, 2022 · Primary completion Jun 30, 2025
Drug: Choline Alfoscerate 400mg; Placebo · For: Alzheimer Disease
Sites: Changwon, South Korea; Incheon, South Korea; Seongnam, South Korea · 4 sites in all
- A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment PatientsPivotal-lookingStatus unknown
Chong Kun Dang PharmaceuticalIndustry
NCT05050604 · 418 participants (planned) · Start Sep 2021 · Primary completion Nov 2024
Drug: Choline Alfoscerate 400mg; Placebo of Choline Alfoscerate 400mg · For: Vascular Cognitive Impairment
Sites: Seoul, South Korea
- A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive ImpairmentPivotal-lookingStatus unknown
Chong Kun Dang PharmaceuticalIndustry
NCT05041790 · 418 participants (planned) · Start Sep 30, 2021 · Primary completion Nov 30, 2024
Drug: Choline Alfoscerate; Placebo · For: Mild Cognitive Impairment
Sites: Seoul, South Korea
- The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no DementiaPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT01363648 · 222 participants · Start Nov 2010 · Primary completion Mar 2013
Drug: choline alfoscerate; placebo (for choline alphoscerate) · For: Cognitive Impairment; Stroke
Sites: Seongnam, South Korea
- Choline Supplementation During Pregnancy: Impact on Attention and Social WithdrawalPivotal-lookingCompleted
University of Colorado, DenverAcademic, hospital or other
NCT03028857 · 216 participants · Start Jun 12, 2017 · Primary completion Dec 22, 2025
Drug: Choline; Placebo · For: Child Development; Prenatal Stress
Sites: Aurora, Colorado; Denver, Colorado
- Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver DiseasesPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02517385 · 147 participants · Start Aug 2015 · Primary completion Jun 2016
Drug: Phosphatidylcholine · For: Hepatic and Hepatobiliary Disorders
Sites: Moscow, Russia
- Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain DevelopmentPivotal-lookingRecruiting
University of Colorado, DenverAcademic, hospital or other
NCT06379971 · 140 participants (planned) · Start Nov 25, 2024 · Primary completion Apr 30, 2029
Drug: Placebo; Choline · For: Child Development; Cannabis Use
Sites: Aurora, Colorado
- A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer PatientsPivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT02648906 · 128 participants (planned) · Start Jul 2015 · Primary completion Nov 2018
Drug: Choline alfoscerate; Placebo · For: Alzheimer Disease
Sites: Sungnam, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malaise47
- pyrexia43
- vomiting30
- nausea29
- chills26
- dyspnoea26
- body temperature increased19
- death18
- device related infection17
- tremor17
- diarrhoea16
- abdominal pain15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2014 | 19 |
| 2015 | 7 |
| 2016 | 22 |
| 2017 | 23 |
| 2018 | 72 |
| 2019 | 40 |
| 2020 | 13 |
| 2021 | 19 |
| 2022 | 22 |
| 2023 | 32 |
| 2024 | 25 |
| 2025 | 13 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effect of a novel toothpaste in children with white spot lesions.
Yilmaz MA, Gokkaya B, Yildiz PK, et al. · J Pak Med Assoc 2022 · Randomized Controlled Trial
- [Knockdown of PCSK9 inhibits endothelial-to-mesenchymal transition of human aortic endothelial cells].
Jin T, Chen L, Liu Y, et al. · Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2021 · Randomized Controlled Trial
- Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation.
Lewis RV, Tregaskis B, McLay J, et al. · Eur J Clin Pharmacol 1990 · Clinical Trial, Randomized Controlled Trial
- Design and characterization of emulsified spray dried alginate microparticles as a carrier for the dually acting drug roflumilast.
Mahmoud AA, Elkasabgy NA, Abdelkhalek AA · Eur J Pharm Sci 2018 · Randomized Controlled Trial
- MR colonography: optimized enema composition.
Luboldt W, Frohlich JM, Schneider N, et al. · Radiology 1999 · Clinical Trial, Comparative Study
- Glycerophosphate does not interact with components of parenteral nutrition.
Topp H, Hochfeld O, Bark S, et al. · Pharmacology 2011 · Randomized Controlled Trial
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.